Medexus Schedules Third Fiscal Quarter 2025 Conference Call
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has announced its upcoming third fiscal quarter 2025 conference call, scheduled for Thursday, February 6, 2025, at 8:00 am Eastern Time. The company will discuss financial results for the quarter ended December 31, 2024, with financial statements and MD&A expected to be filed after market close on February 5, 2025.
The call will be accessible via toll-free numbers for Canadian and U.S. callers (888-506-0062) and international callers (+1 973-528-0011) using access code 571655. A live webcast will be available on Medexus's corporate website's Investors section. A replay will be accessible until February 13, 2025, through dedicated phone numbers, and the webcast recording will remain available until February 6, 2026.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) ha annunciato la sua prossima conferenza telefonica per il terzo trimestre fiscale 2025, programmata per giovedì 6 febbraio 2025, alle 8:00 ora orientale. L'azienda discuterà i risultati finanziari per il trimestre conclusosi il 31 dicembre 2024, con i bilanci e il MD&A previsti per essere presentati dopo la chiusura del mercato il 5 febbraio 2025.
La chiamata sarà accessibile tramite numeri verdi per i chiamanti canadesi e statunitensi (888-506-0062) e per i chiamanti internazionali (+1 973-528-0011) utilizzando il codice di accesso 571655. Sarà disponibile una diretta streaming sul sito web aziendale di Medexus nella sezione Investitori. Una registrazione della chiamata sarà accessibile fino al 13 febbraio 2025, tramite numeri telefonici dedicati, e la registrazione della diretta streaming resterà disponibile fino al 6 febbraio 2026.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) ha anunciado su próxima llamada de conferencia para el tercer trimestre fiscal 2025, programada para jueves 6 de febrero de 2025, a las 8:00 am hora del Este. La empresa discutirá los resultados financieros para el trimestre que finalizó el 31 de diciembre de 2024, con los estados financieros y el MD&A que se presentarán después del cierre del mercado el 5 de febrero de 2025.
La llamada será accesible a través de números gratuitos para los llamantes canadienses y estadounidenses (888-506-0062) y para los llamantes internacionales (+1 973-528-0011) utilizando el código de acceso 571655. Habrá una retransmisión en vivo disponible en la sección de Inversores del sitio web corporativo de Medexus. Una repetición estará accesible hasta el 13 de febrero de 2025, a través de números de teléfono dedicados, y la grabación de la retransmisión estará disponible hasta el 6 de febrero de 2026.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)는 2025 회계연도 3분기 컨퍼런스 콜을 2025년 2월 6일 목요일, 동부 표준시 오전 8시로 예정하고 있음을 발표했습니다. 회사는 2024년 12월 31일 마감된 분기의 재무 결과에 대해 논의할 것이며, 재무 제표와 MD&A는 2025년 2월 5일 시장 마감 후 제출될 예정입니다.
콜은 캐나다 및 미국의 발신자(888-506-0062)와 국제 발신자를 위한 무료 전화 번호(+1 973-528-0011)를 통해 접근할 수 있으며, 액세스 코드 571655를 사용해야 합니다. Medexus의 기업 웹사이트 투자자 섹션에 실시간 웹캐스트가 제공될 것입니다. 반복 재생은 2025년 2월 13일까지 전용 전화 번호를 통해 가능하며, 웹캐스트 녹화는 2026년 2월 6일까지 제공될 것입니다.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) a annoncé sa prochaine conférence téléphonique pour le troisième trimestre fiscal 2025, prévue pour jeudi 6 février 2025, à 8 h 00 heure de l'Est. L'entreprise discutera des résultats financiers pour le trimestre se terminant le 31 décembre 2024, avec les états financiers et le MD&A qui devraient être déposés après la clôture du marché le 5 février 2025.
La conférence sera accessible par des numéros gratuits pour les appelants canadiens et américains (888-506-0062) ainsi que pour les appelants internationaux (+1 973-528-0011) en utilisant le code d'accès 571655. Un webinaire en direct sera disponible dans la section Investisseurs du site web de Medexus. Un enregistrement sera accessible jusqu'au 13 février 2025 via des numéros de téléphone dédiés, et l'enregistrement du webinaire restera disponible jusqu'au 6 février 2026.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) hat seine bevorstehende Telefonkonferenz für das dritte Fiskalquartal 2025 angekündigt, die für Donnerstag, den 6. Februar 2025, um 8:00 Uhr Eastern Time geplant ist. Das Unternehmen wird die Finanzergebnisse für das am 31. Dezember 2024 endende Quartal besprechen, wobei die Finanzberichte und der MD&A nach Marktschluss am 5. Februar 2025 eingereicht werden sollen.
Die Telefonkonferenz ist für kanadische und US-Anrufer über gebührenfreie Nummern (888-506-0062) sowie für internationale Anrufer (+1 973-528-0011) unter Verwendung des Zugangscodes 571655 zugänglich. Ein Live-Webcast wird auf der Investorenseite der Unternehmenswebsite von Medexus verfügbar sein. Eine Wiederholung wird bis zum 13. Februar 2025 über spezielle Telefonnummern zugänglich sein, und die Aufzeichnung des Webcasts bleibt bis zum 6. Februar 2026 verfügbar.
- None.
- None.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 6, 2025 to discuss Medexus's results for its third fiscal quarter ended December 31, 2024. Medexus expects to file its financial statements and MD&A after markets close on February 5, 2025.
To participate in the call, please dial the following numbers:
888-506-0062 (toll-free) for Canadian and U.S. callers
+1 973-528-0011 for international callers
Access code: 571655
A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link:
https://www.webcaster4.com/Webcast/Page/2010/51991
A replay of the call will be available approximately one hour following the end of the call through Thursday, February 13, 2025. To access the replay, please dial the following numbers -
877-481-4010 for Canadian and U.S. callers
+1 919-882-2331 for international callers
Conference ID: 51991
A replay of the webcast will be available on the Investors section of Medexus's corporate website until Friday, February 6, 2026.
About Medexus
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.com.
Contacts
Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Forward-Looking statements
Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239244
FAQ
When will Medexus (MEDXF) release its Q3 2025 financial results?
What time is Medexus (MEDXF) Q3 2025 earnings conference call?
How can investors access Medexus (MEDXF) Q3 2025 earnings call?
How long will the replay of Medexus (MEDXF) Q3 2025 earnings call be available?
